Safety and Immunogenicity of DNA/Modified Vaccinia Virus Ankara Malaria Vaccination in African Adults

Journal of Infectious Diseases

Volumn 188, Issue 8, 2003, Pages 1239-1244

  Moorthy, Vasee S ^a,b   Pinder, Margaret ^a   Reece, William H H ^b   Watkins, Kate ^b   Atabani, Sowsan ^a   Hannan, Carolyn ^b   Bojang, Kalifa ^a   McAdam, Keith P W J ^a   Schneider, Joerg ^b   Gilbert, Sarah ^b   Hill, Adrian V S ^b,c  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; MALARIA VACCINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; MULTIPLE EPITOPE THROMBOSPONDIN RELATED ADHESION PROTEIN; RECOMBINANT VACCINE; THROMBOSPONDIN; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AFRICA; ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ARM MOVEMENT; ARTHRALGIA; ARTICLE; BULLOUS SKIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DNA MODIFICATION; DNA SEQUENCE; DRUG SAFETY; EFFECTOR CELL; EPITOPE MAPPING; ERYTHEMA; FEVER; GAMBIA; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE; MALAISE; MALARIA; MEMORY CELL; MOTOR DYSFUNCTION; MYALGIA; NAUSEA; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; POPULATION EXPOSURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN INDURATION; VACCINATION; VACCINIA VIRUS;

ADULT; AFRICA; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNIZATION SCHEDULE; LYMPHOCYTE ACTIVATION; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINES, DNA; VACCINIA VIRUS;

EID: 0242364645     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/378515     Document Type: Article

References (17)

1. World Health Organization (WHO). Malaria sheet no. 94. Geneva: WHO, 1996.
2. Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol 2000; 165:1453-62.
3. Hill AV, Allsopp CE, Kwiatkowski D, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595-600.
4. Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998; 4:397-402.
5. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
6. McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69:681-6.
7. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
8. Mayr A. Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine [in German]. Berl Munch Tierarztl Wochenschr 1999; 112:322-8.
9. Gilbert SC, Plebanski M, Harris SJ, et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997; 15:1280-4.
10. Flanagan KL, Plebanski M, Akinwunmi P, et al. Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein of Plasmodium falciparum in West Africans. Eur J Immunol 1999; 29:1943-54.
11. McConkey S, Reece WHH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9:729-35.
12. Moorthy VS, McConkey S, Roberts M, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003; 21:2004-11.
13. Miyahira Y, Garcia-Sastre A, Rodriguez D, et al. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8(+) responses in mice. Proc Natl Acad Sci USA 1998; 95:3954-9.
14. Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998; 394:482-5.
15. Tsuji M, Romero P, Nussenzweig RS, Zavala F. CD4+ cytolytic T cell clone confers protection against murine malaria. J Exp Med 1990; 172: 1353-7.
16. Moreno A, Clavijo P, Edelman R, et al. Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int Immunol 1991; 3:997-1003.
17. Homann D, Teyton L, Oldstone MB. Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med 2001; 7:913-9.